By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Astellas Pharma Inc. 

3-11 Nihonbashi-Honcho 2-chome

Chuo-ku  Tokyo  103-8411  Japan
Phone: 81-3-3244-3000 Fax: 81-3-3244-3272


SEARCH JOBS


Industry
Healthcare

Segment
Pharmaceuticals

Collaborations

Gilead (Durham, NC) 





Company News
Vical Incorporated (VICL) Expands Infectious Disease Portfolio With Novel Antifungal From Astellas Pharma Inc. (ALPMY) 3/26/2015 11:09:54 AM
Astellas Pharma Inc. (ALPMY) And Medivation, Inc. (MDVN) Announce New Enzalutamide Data Presented During Plenary Presentations At The 2015 European Association Of Urology Congress 3/24/2015 9:42:26 AM
Astellas Pharma Inc. (ALPMY) Receives FDA Approval for CRESEMBA (isavuconazonium sulfate) For The Treatment Of Invasive Aspergillosis And Invasive Mucormycosis 3/9/2015 6:55:23 AM
Astellas Pharma Inc. (ALPMY) Broadens Regional Leadership And Creates New Corporate Affairs And Corporate Development Functions 2/20/2015 8:39:37 AM
Astellas Pharma Inc. (ALPMY) Launches The Newest Element In Its Global Corporate Brand Campaign On CNN's Global Broadcast Network 2/16/2015 11:39:06 AM
Astellas Pharma Inc. (ALPMY) Broadens Commitment to Clinical Trial Data Transparency 2/2/2015 11:06:37 AM
Astellas Pharma Inc. (ALPMY). Immunomic Therapeutics Forge $70 Million Vaccine Pact 1/30/2015 6:28:48 AM
Astellas Pharma Inc. (ALPMY) Announces FDA Anti-Infective Drugs Advisory Committee Recommends Approval Of CRESEMBA┬« (Isavuconazonium) For Treatment Of Invasive Aspergillosis And Mucormycosis 1/23/2015 7:03:11 AM
FDA Panel Backs Astellas Pharma Inc. (ALPMY)'s CRESEMBA for Invasive Fungal Infections 1/22/2015 7:36:47 AM
Astellas Pharma Inc. (ALPMY) Hires Global Executive Eric Terhaerdt To Lead Global Development Operations 1/15/2015 9:58:50 AM
12345678910...
//-->